Effector Therapeutics Inc (EFTR)

$1.94 0.04 (2.02%)

16:00 EDT EFTR Stock Quote Delayed 30 Minutes

EFTR Stock Earnings: eFFECTOR Therapeutics Meets EPS for Q1 2024

By InvestorPlace Earnings May 9, 2024

EFTR stock results show that eFFECTOR Therapeutics met analyst estimates for earnings per share the first quarter of 2024.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

EFTR Stock Earnings: eFFECTOR Therapeutics Misses EPS for Q4 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

More Articles

Volume:

Previous Close -

Market Cap -

PE Ratio -

EPS -

Volume (Avg. Vol.) 61,594

Day's Range $1.92 - $2.00

52-Week Range $0.36 - $17.75

Dividend & Yield N/A (N/A)

EFTR Stock Predictions, Articles, and Effector Therapeutics Inc News

From InvestorPlace
From the Web

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

By William White, InvestorPlace Writer Nov 13, 2023

Pre-market stock movers are worth checking out on Monday as we cover all of the biggest gainers and losers this morning!

3 Promising Biotech Stocks That Will Make Early Investors Rich

By Josh Enomoto, InvestorPlace Contributor Oct 2, 2023

Despite their volatility, certain biotech stocks stand out for their innovative approaches and potential game-changing therapies.

Why Is eFFECTOR Therapeutics (EFTR) Stock Up 75% Today?

By William White, InvestorPlace Writer May 26, 2023

EFFECTOR Therapeutics (EFTR) stock is taking off on Friday after the company reported positive data from a Phase 2 clinical trial.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

By William White, InvestorPlace Writer May 26, 2023

It's time for another dive into the biggest pre-market stock movers as we check out what's happening this morning on Friday!

3 Penny Stocks That Could Turn $1,000 into $10,000 in a Year

By Alex Sirois, InvestorPlace Contributor May 11, 2023

These 3 penny stocks have 10X potential over the next twelve months, providing the right risk/reward bet for certain investors.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

By William White, InvestorPlace Writer Feb 28, 2023

It's time to start the day with a breakdown of the biggest pre-market stock movers traders need to know about on Monday!

Hold Off on eFFECTOR Therapeutics if You Can’t Stomach the Risk

By Josh Enomoto, InvestorPlace Contributor Sep 28, 2021

While EFTR stock has escaped the usual underperformance of SPAC IPOs so far, eFFECTOR Therapeutics still remains a risky proposition.

eFFECTOR Therapeutics Stock Might Be Worth the Risk in Small Quantities

By David Moadel, InvestorPlace Contributor Sep 20, 2021

During the post-SPAC spectacle, EFTR stock be volatile - this should be expected. Still, eFFECTOR's oncology therapies look promising.

EFTR Stock: 7 Things to Know About eFFECTOR as Shares Shoot Up 100%

By Chris MacDonald, InvestorPlace Contributor Sep 8, 2021

Here's what investors may want to know about eFFECTOR and EFTR stock, as the company's shares surge once again today in a big way.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

By William White, InvestorPlace Writer Sep 8, 2021

Welcome back, trader! We're kicking off the day with an overview of the biggest pre-market stock movers for Wednesday to keep an eye on!

EFTR Stock: What Is Going on With Red-Hot eFFECTOR Therapeutics Today?

By Samuel O'Brient, InvestorPlace Reporter Sep 7, 2021

After a tough week for SPACs, EFTR stock has enjoyed significant gains today. The SPAC bubble may not be over yet.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

By William White, InvestorPlace Writer Aug 30, 2021

The weekend is officially over and that means it's time to jump back into investing with a look at Monday's biggest pre-market stock movers!

Effector Therapeutics announces $15M registered direct offering (NASDAQ:EFTR)

From Seeking Alpha Jan 25, 2024

Effector Therapeutics announces a $15 million registered direct offering with a healthcare investor.

eFFECTOR updates Phase 1/2 data for breast cancer therapy

From Seeking Alpha Dec 8, 2023

eFFECTOR Therapeutics (EFTR) announced interim data from a Phase 1/2 trial for a combination therapy involving its breast cancer candidate zotatifin. Read more here.

eFFECTOR stock rises after FDA fast track status for breast cancer therapy (NASDAQ:EFTR)

From Seeking Alpha Nov 28, 2023

eFFECTOR Therapeutics gains 5% premarket after receiving FDA fast track designation for combination therapy in breast cancer treatment.

HC Wainwright starts eFFECTOR at buy, cites drug technology platform (EFTR)

From Seeking Alpha Aug 25, 2023

HC Wainwright initiated coverage of eFFECTOR (EFTR) with a buy rating, citing its proprietary technology platform and near-term catalysts for its oncology drug candidates.

eFFECTOR Therapeutics to launch ~$8.7M registered direct offering (NASDAQ:EFTR)

From Seeking Alpha Jun 7, 2023

eFFECTOR Therapeutics (EFTR) said on Wednesday that the biopharmaceutical company is set to offer 7.8M shares at $1.125 per share in an ~$8.7M registered direct offering.

Analysts’ Top Healthcare Picks: CureVac (CVAC), eFFECTOR Therapeutics (EFTR)

From TipRanks Nov 17, 2022

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on CureVac (

ADVERTISEMENT